Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1833278 | 0.91 | POLB (0.40) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL20483615 | 0.91 | POLB (0.40) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL4288590 | 0.89 | POLB (0.41) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL4289426 | 0.84 | POLB (0.38) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL69496 | 0.83 | ALDH1A1 (0.46) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL18134201 | 0.83 | ALDH1A1 (0.46) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL2069818 | 0.82 | POLB (0.42) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL19766 | 0.82 | POLB (0.42) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL136687 | 0.82 | ATM (0.44) | POLBATMOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL6789531 | 0.81 | ATM (0.41) | POLBATMOPRM1SMN1; SMN2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250263394-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | INVENTISBIO LLC | 2025-08-21 | — | — | US | disclosed |
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4568951-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4562014-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119894898-A | Compounds, methods of preparation and uses thereof | 益方生物科技(上海)股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119654314-A | Heterocyclic amide and urea compounds as JAK2 inhibitors | 艾捷斯治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4509507-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| CN-119095846-A | Compounds, methods of preparation and uses thereof | 益方生物科技(上海)股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-30 | — | — | US | disclosed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| US-7371778-B2 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2008-05-13 | — | — | US | disclosed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | disclosed |
| US-20050256185-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2005-11-17 | — | — | US | disclosed |
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1373247-A2 | SPIROISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002079189-A2 | SPIROISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION AND INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2002-10-10 | — | — | WO | disclosed |
| US-5114960-A | Rheumatoid arthritis; antiinflammatory and antishock agents; gastrointestinal and respiratory system disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-05-19 | — | — | US | disclosed |
| EP-0409273-A2 | Substituted isoxazole and isothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263394-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | PIK3CD, PIK3CA, PIK3C2B | POLB 1760/4885ATM 627/4885OPRM1 4654/4885 |
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | POLB 1764/4885ATM 114/4885OPRM1 1904/4885 |
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | POLB 3058/4885ATM 4418/4885OPRM1 2029/4885 |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | POLB 4135/4885ATM 2939/4885OPRM1 1840/4885 |
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | KRAS, NRAS, HRAS | POLB 972/4885ATM 2768/4885OPRM1 1470/4885 |
| US-20050256185-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | DHODH, THPO, SQLE | POLB 3765/4885ATM 3050/4885OPRM1 1967/4885 |
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK1 | POLB 126/4885ATM 1077/4885OPRM1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.